We’ve recently updated our valuation analysis.

REGENXBIO Valuation

Is RGNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGNX?

Other financial metrics that can be useful for relative valuation.

RGNX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA4.1x
PEG Ratio-9.1x

Price to Earnings Ratio vs Peers

How does RGNX's PE Ratio compare to its peers?

RGNX PE Ratio vs Peers
The above table shows the PE ratio for RGNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average21.9x
ALEC Alector
21.5x-25.2%US$781.1m
DVAX Dynavax Technologies
5.8x-45.7%US$1.3b
RCUS Arcus Biosciences
28.3x26.7%US$1.9b
AGEN Agenus
32.1x1.5%US$580.5m
RGNX REGENXBIO
12.6x-1.4%US$1.1b

Price-To-Earnings vs Peers: RGNX is good value based on its Price-To-Earnings Ratio (12.6x) compared to the peer average (21.9x).


Price to Earnings Ratio vs Industry

How does RGNX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Earnings vs Industry: RGNX is good value based on its Price-To-Earnings Ratio (12.6x) compared to the US Biotechs industry average (14.9x)


Price to Earnings Ratio vs Fair Ratio

What is RGNX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGNX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.6x
Fair PE Ratio19.6x

Price-To-Earnings vs Fair Ratio: RGNX is good value based on its Price-To-Earnings Ratio (12.6x) compared to the estimated Fair Price-To-Earnings Ratio (19.6x).


Share Price vs Fair Value

What is the Fair Price of RGNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RGNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RGNX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies